Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 2von Hippel-Lindau Disease 1Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Sarcoma 1Neoplasm Metastasis 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1Liposarcoma 1Leiomyosarcoma 1Hamartoma Syndrome, Multiple 1Glioma 1Glioblastoma 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Renal Cell 1Brain Neoplasms 1Bone Neoplasms 1Autistic Disorder 1Astrocytoma 1

Interventions

pembrolizumab 14Paclitaxel 13Carboplatin 12Bevacizumab 7Specimen Handling 6Cisplatin 6olaparib 5Taxes 5Fulvestrant 5Nivolumab 4Megestrol Acetate 4Magnetic Resonance Spectroscopy 4Biopsy 4palbociclib 3durvalumab 3Oxaliplatin 3Leucovorin 3Letrozole 3Immunoglobulin G 3Fluorouracil 3Doxorubicin 3Docetaxel 3Disulfides 3trastuzumab deruxtecan 2ribociclib 2pertuzumab 2lenvatinib 2ipatasertib 2dostarlimab 2capivasertib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Everolimus × 30 days × Clear all
NCT03008408 2026-05-22

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
90 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡